Ann: 2022 Annual Report, page-9

Finally got a chance to have a good read of it all and certainly well presented.

Great to see an initial case study for AnteoX hopefully more of these to follow and an additional case study tab to the website wouldn’t go astray.

Also have done a bit of light reading this evening on the Procalcitonin testing and how it’s being utilised.
Looks like a great way to reduce overprescribed antibiotics for COPD patients along with ruling out or in a range of possible conditions.
This will likely be a very large growth market COPD is already one of the leading health issues globally and with Covid running a muck in lungs worldwide expect this market won’t slow down anytime soon.
Will hopefully be of great use for patient outcomes and reduce over subscription of antibiotics which is a real problem
It is also is a good alignment for initial Eugeni test markets - Example you enter the emergency department, respiratory clinic or doctors surgery with a chest issue or cough- take a Eugeni covid/flu multi test to advise treatment and rule them in or out then at the same time run a Eugeni PCT to rule out any bacterial infection and advise antibiotic use or not.
Magically 15-20min later you have your answer (covid/flu/bacterial infection) and begin a treatment plan.
Looks like a winning strategy for hospitals and clinics.

couple of recent papers here that are worth a read for anyone interested.

https://www.ncbi.nlm.nih.gov/books/NBK539794/

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7850181/